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Background: Postmenopausal women experience estrogen deficiency-related menopausal symptoms (e.g., hot
flashes and mood swings) and a dramatic increase in the incidence of chronic diseases. Although
estrogen-replacement therapy (ERT) can reduce mortality from cardiovascular disease and improve osteoporosis
and menopausal symptoms, its side effects have limited recent use. This study investigated the estrogen-like activity
of aqueous extract from Agrimonia pilosa Ledeb.
Methods: The estrogenic activity of A. pilosa was investigated by using several in vitro assays. The binding activity
of A. pilosa on estrogen receptors was examined using a fluorescence polarization-based competitive binding assay.
The proliferative activity of A. pilosa was also examined using MCF-7 cells. Furthermore, the effect of A. pilosa on the
expression of 3 estrogen-dependent genes was assessed.
Results: Using liquid chromatography-mass spectrometry, the 3 major peaks of A. pilosa aqueous extract were
identified as apigenin-hexose, luteolin-glucuronide, and apigenin-glucuronide. The aqueous extract induced the
proliferation of estrogen receptor-positive MCF-7 cells (p < 0.05). A. pilosa-stimulated proliferation was blocked on
adding the estrogen antagonist ICI 182,780. Moreover, A. pilosa treatment increased the mRNA expression of the
estrogen-responsive genes pS2 and PR (p < 0.05).
Conclusions: These results suggest A. pilosa can be used to improve estrogen deficiency-related menopausal
symptoms or to treat diseases in postmenopausal women.
Keywords: MCF-7 proliferation assay, Estrogenic activity, Agrimonia pilosa, Metabolic syndromeBackground
Postmenopausal women experience estrogen deficiency-
related menopausal symptoms, including hot flashes,
mood swings, and sweating [1]. Postmenopausal women
also exhibit a dramatic increase in the risk of metabolic
syndrome, cognitive deficits, cardiovascular disease, dys-
lipidemia, and osteoporosis [2-5]. As the population ages
and life expectancy increases, the importance of prevent-
ing and/or improving menopause-related changes has
become paramount [6].
Hormone replacement therapy (HRT) can reduce mor-
tality from cardiovascular disease and improve osteopor-
osis and menopausal symptoms [7]. In addition, Daly* Correspondence: ymlee@korea.kr
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reproduction in any medium, provided the oret al. reported that quality of life significantly improved
after HRT [8]. However, many studies have shown that
HRT is no longer a good solution for the treatment of
menopausal women because of the increased risk of
breast and endometrial cancers associated with long-
term estrogen-replacement therapy (ERT) [9,10].
Phytoestrogens, that is, plant-derived estrogens, are
found naturally in a diverse range of foods and include
isoflavones, lignans, coumestans, and flavonoids (e.g.,
quercetin and kaempferol). Because the structure of phy-
toestrogens is similar to that of human estrogen, phy-
toestrogens can bind to estrogen receptors (ERs) [11].
Much scientific effort has been put into the search for
additional phytoestrogens showing estrogen-like activity,
leading to the continuous discovery of novel phytoestro-
gens in nature [12,13].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-cancer [14], anti-oxidant [15], acetylcholinesterase
inhibitory [16], and anti-inflammatory activities [17,18].
Some chemical studies have reported that A. pilosa con-
tains phenolic compounds such as agrimonin, catechin,
quercetin, and rutin [19,20]. However, the estrogenic
effects of aqueous extract from A. pilosa have not yet
been examined.
The purpose of this study was to investigate the estro-
genic activity of A. pilosa by using several in vitro assays.
The binding activity of A. pilosa on estrogen receptors
was examined using a fluorescence polarization-based
competitive binding assay. The proliferative activity of A.
pilosa was also examined using MCF-7 cells. Further-
more, the effect of A. pilosa on the expression of 3
estrogen-dependent genes was assessed.
Methods
Plant material and extraction
The aerial parts of A. pilosa were purchased from
Kyungdong Market (Seoul, Korea) in dried form and
identified by the Classification and Identification Com-
mittee of the Korea Institute of Oriental Medicine
(KIOM). A voucher specimen (KIOM109-122Aa) has
been deposited at the herbarium of the Department of
Herbal Resources Research of the KIOM. Each of the
dried components was extracted twice with 10 volumes
of water at 80°C for 3 h. The extracts were filtered
through filter paper (Whatman, Maidstone, UK) and
were concentrated under reduced pressure by a rotary
evaporator (EYELA, Tokyo, Japan) at 40°C. The water
filtrates were frozen and lyophilized. The lyophilized
extracts were stored at −20°C until use.
Analysis of A. pilosa aqueous extract composition
The chemical composition of the A. pilosa aqueous ex-
tract was determined using liquid chromatography-mass
spectrometry (LC-MS). Briefly, aqueous extracts of A.
pilosa were subjected to ultra-high performance liquid
chromatography-mass spectrometry (UHPLC-MS) ana-
lysis. LC-MS was performed using a LTQ Orbitrap XL
linear ion trap mass spectrometer system (Thermo
Fisher Scientific Co., Waltham, MA) equipped with an
electrospray ionization source. The UHPLC separations
were performed with an Accela UHPLC system (Thermo
Fisher Scientific) by using an Acquity BEH C18 column
(1.7 μm, 100 × 2.1 mm; Waters Corp., Milford, MA).
Mobile phase A was water and phase B was acetonitrile,
where both phases contained 0.1% formic acid. The gra-
dient elution, at a flow rate of 0.3 mL/min, was per-
formed as follows: 0–1 min, 1% B (isocratic); 1–15 min,
1–30% B (linear gradient); 15–20 min, 30–60% B (linear
gradient); 20–25 min, 60–100% B (linear gradient); and
25–27 min 100% B (isocratic). Full-scan mass spectrawere obtained using the negative-ion mode at with an
m/z range of 100–1000. Data-dependent tandem mass
spectrometry (MSn) experiments were controlled by
menu-driven software provided with the Xcalibur system
(Thermo Fisher Scientific).
ERα- and ERβ-binding assays
Estrogen receptor-binding ability was examined using an
estrogen receptor (ER) competitive binding assay kit
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions. The relative affinity of the test
material for ER was determined by the change in
polarization value (Molecular Devices Inc., Sunnyvale,
CA) in the presence of a test plant.
Cell culture
MCF-7, an ER-positive human breast cancer cell line,
was purchased from the Korean Cell Line Bank (Seoul,
Korea) and cultured in RPMI-1640 containing 10%
fetal bovine serum and penicillin-streptomycin solution
(100 units/mL penicillin and 100 μg/mL streptomycin;
Hyclone Laboratories, Inc., South Logan, UT). The cells
were grown at 37°C in a humidified atmosphere of 95%
air/5% CO2. The medium was renewed 2–3 times per
week, and before reaching confluence, the cells were
subcultured every 3–4 days in a 1: 4 ratio.
Proliferation assay of MCF-7 cells (E-screen assay)
Confluent MCF-7 cells were washed twice with
phosphate-buffered saline (PBS) (Hyclone Laboratories)
and 0.05% trypsin-EDTA solution (Invitrogen) was
added for 1 min. After trypsin-EDTA was removed, the
culture was left at room temperature (~20°C) for 5–
10 min; subsequently, the cells were detached, resus-
pended in RPMI-1640 medium, counted, and seeded
into 24-well plates at a density of 2 × 104 cells/well in
normal growth medium. After 24 h, the cells were
completely attached to the well bottom; the medium
was then aspirated and estrogen-free medium con-
taining both phenol-red-free RPMI (Invitrogen) and
5% charcoal-dextran-stripped human serum (Hyclone
Laboratories) was added. MCF-7 cells were treated
with different concentrations of test material and
were cultured for 144 h. In addition, test material were
added to the medium at some concentrations where they
showed estrogenic activity, either with or without
the ER-antagonist ICI 182,780 (Tocris, Bristol, UK).
17β-Estradiol and PBS were used as the positive and nega-
tive controls, respectively.
MTT proliferation assay
Cell proliferation was assessed after 7 d in culture, using
the MTT proliferation assay. After the incubation
period, cells were added with 100 μL of 5 mg/mL
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MO) solution/well and were incubated further for 4 h in
a humidified atmosphere (37°C in 5% CO2). The
medium was replaced with 1 mL dimethyl sulfoxide
(DMSO). The absorbance was measured at 540 nm in a
microplate reader (Molecular Devices Inc., Sunnyvale,
CA). Cell proliferation was expressed as percentage
values compared with the negative PBS control, which
was considered to represent 100% cell proliferation.
RNA isolation
MCF-7 cells were seeded in 75-cm2 culture flasks at a
density of 2 × 104 cells/cm2 in RPMI-1640 medium and
incubated at 37°C at 5% CO2. On the following day, the
medium was shifted to estrogen-free medium containing
phenol-red-free RPMI (Invitrogen) and 5% charcoal-
dextran-stripped human serum (Hyclone Laboratories)
with controls or test material. After the cells were incu-
bated for 24 h at 37°C and 5% CO2, they were washed
twice with PBS, and total RNA was extracted from cells
using the RNeasy Plus Mini Kit (Qiagen, Venlo, Nether-
lands), according to the manufacturer’s protocol. The
quantity and purity of the total RNA obtained were
determined on the basis of the absorbance at 260 and
280 nm. RNA quality was determined by gel electro-
phoresis on 2% agarose gels stained with ethidium brom-
ide (0.5 μg/mL). RNA samples were stored at −20°C
until use.
Real-time RT-PCR
The expression levels of estrogen-dependent genes were
determined by a real-time one-step RT-PCR performed
using the SYBR Green PCR master mix (Qiagen) and a
thermal cycler Rotor-Gene 3000 (Corbett Research, Mor-
tlake, Australia), in accordance with the manufacturer’s
protocol. The primer sequences for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), pS2, progesterone









One step RT-PCR was performed as follows: (1) re-
verse transcription at 50°C for 30 min; (2) initial de-
naturation at 95°C for 15 min; and (3) 40 cycles of
denaturation at 95°C for 30 s, annealing at 60°C for 30 s,
and elongation at 72°C for 30 s. Melting-curve analysis
was performed at 72–95°C to verify the specificity of
amplification and was supplemented with 2% agarose
gel electrophoresis of randomly selected samples. Therelative quantitation values were calculated by analyzing
the changes in SYBR Green fluorescence during PCR,
according to the manufacturer’s instructions. Ct values
were defined as the threshold cycles at which a statisti-
cally significant increase occurred in the intensity of
SYBR Green emission. Using the 2-ΔΔCt method, the
changes (in orders of magnitude) relative to the control
were calculated. Ct values were normalized to those for
the housekeeping gene, GAPDH and the ΔCt values of
the A. pilosa-treated cells were normalized to the mean
ΔCt values of the controls.Statistical analysis
Data was expressed as mean ± SD values. Cell prolifera-
tion was expressed as percentage values compared with
that for the negative PBS control, which was taken to
represent 100% cell proliferation. Duncan’s multiple
range tests were used to detect differences between
groups when analysis of variance was significant at p <
0.05. Student’s t-test was used to establish significant dif-
ferences between any 2 groups.Results
HPLC analysis of A. pilosa aqueous extract for constituent
flavonoids
A. pilosa aqueous extract was examined for its flavonoid
composition by simultaneous estimation using negative
ion-mode tandem mass analysis (MS2 and MS3). Individ-
ual constituents were identified by analysis of the MS2
and MS3 tandem mass spectrum (Figure 1). The 3 major
peaks of the A. pilosa aqueous extract were identified as
apigenin-hexose ([M-H]-, m/z 449.3) at an RT of 10.62
min, luteolin-glucuronide ([M-H]-, m/z 461.3) at an RT
of 11.39 min, and apigenin-glucuronide ([M-H]-, m/z
445.3) at an RT of 12.62 min. The sugar moiety was
defined by MS2 fragment ion analysis. The aglycone
structure of MS3 spectra was identified by an MS/MS
spectrum library search [21]. The percentage content of
each flavonoid was estimated with the relative peak area
based on PDA (200–500 nm) data. The flavonoids
present in the extract included apigenin-glucuronide
(21.81%), apigenin-hexose (19.46%), and luteolin-
glucuronide (13.03%).Competitive binding of A. pilosa to estrogen receptors
To evaluate the estrogenic activity of the aqueous extract
from A. pilosa, the ability of A. pilosa to bind ERα and
ERβ was assessed using a competitive binding assay
based on fluorescence polarization. As shown Figure 2,
this aqueous extract could bind ERs and displaced E2-
bound ERα and ERβ.
Figure 1 Results of UPLC-MS analysis of the 3 main compounds of A. pilosa aqueous extract. (a) Chromatogram at 350 nm, (b) mass
spectrum of apigenin-hexose ([M-H]-, m/z 449.3) at an RT of 10.62 min, (c) luteolin-glucuronide ([M-H]-, m/z 461.3) at an RT of 11.39 min, and (d)
apigenin-glucuronide ([M-H]-, m/z 445.3) at an RT of 12.62 min.
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In the E-SCREEN assay using MCF-7 cells, the prolifera-
tive effect of the aqueous extracts from A. pilosa was
evaluated relative to that of the negative control (PBS;
Figure 3). As a positive control, the estrogenic effect of
17β-estradiol on the proliferation in MCF-7 cells was
measured. 17β-Estradiol caused significant proliferation
in MCF-7 cells at concentrations of 10-10–10-8 M with-
out cytotoxic activity (p < 0.001), and the highest prolif-
erative effect was observed at 10-9 M. A. pilosa induced
significant stimulation of MCF-7 cell proliferation at
concentrations of 1 and 10 μg/mL (p < 0.001). When A.
pilosa extracts were co-treated with E2, A. pilosa did not
antagonize E2 activity in MCF-7 cells (Figure 4).
ER-dependent action of A. pilosa in MCF-7 cells
To investigate whether the MCF-7 cell proliferation
induced by A. pilosa is mediated via the ER, cells were
incubated with aqueous extract from A. pilosa in the
presence or absence of the estrogen antagonist, ICI182,780 (100 nM). The proliferation induced by A. pilosa
and E2 was blocked by addition of ICI 182,780 (Figure 5)
indicating an ER-dependent mechanism for the estro-
genic effects on MCF-7 cell proliferation.Effect of A. pilosa on the mRNA levels of estrogen-
dependent genes
Three estrogen-dependent genes, pS2, PR, and cathepsin
D, in MCF-7 cells were selected for investigating the A.
pilosa-induced transcriptional response through ER
binding. These genes are rapidly and strongly induced
by estrogens and indicate estrogenic activity [13,22,23].
Furthermore, these genes are expressed in the MCF-7
breast cancer cells used in the current study and are
regulated by estrogen [24-26]. As shown in Figure 6, es-
trogen induced pS2 (>3-fold), PR (>8-fold), and cathe-
psin D (>2-fold) gene expression with respect to the
control. A. pilosa treatment also elicited an increase in
the mRNA expression of pS2, PR, and cathepsin D,
(a) (b) 
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Figure 2 Competitive binding curves illustrating the binding of A. pilosa to ERα and ERβ. The results are expressed as mean ± SD values.
(a) The binding affinity of E2 to ERα and ERβ, and (b) the binding affinity of A. pilosa to ERα and ERβ.
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Discussion
Recent concerns have been raised regarding the side
effects of the prolonged use of ERT, including an
increased risk of breast and endometrial cancers. As a
result, research focused on identifying natural agents
with estrogen-like activity for the treatment of estrogen
deficiency has increased. In light of this increased inter-
est, dozens of edible wild plants have been screened with
the goal of identifying estrogenic activity as a part of the
search for new phytoestrogens. Of the plants tested,
aqueous extracts from the aerial parts of A. pilosa have
demonstrated estrogenic activity. A. pilosa is a tradi-
tional medicinal plant possessing anti-carcinogenic prop-
erties, anti-oxidant, and anti-inflammatory properties,(a) (b
Figure 3 Effect of (a) E2 (17-β estradiol) and (b) aqueous extracts of A
as representative data from three independent experiments. Results are exp
using the Student’s t test. *** p < 0.001.and acetylcholinesterase inhibitory effects. However, little
is known about the estrogenic activity of the A. pilosa
aqueous extract.
Since the first step in the activation of ERs involves
the binding of a ligand, measurement of ligand binding
is important in characterizing the potential estrogenicity
of test materials [27]. Therefore, the binding affinity of
A. pilosa aqueous extract to ERs was first measured, and
subsequently, A. pilosa was thought to bind to ERs by
displacing E2 binding. The binding of estrogens or se-
lective estrogen-receptor modulators to ERs initiates a
molecular signaling cascade resulting in the transcrip-
tional regulation of specific genes and protein synthesis
[28]. Next, a proliferation assay was performed to assess
the estrogen-like physiologic action of A. pilosa aqueous
extract. Estrogens are known stimulants of cellular pro-
liferation and the E-Screen assay measures the effects of) 
. pilosa on the proliferation of MCF-7 cells. Figures were selected
ressed as mean ± SD values. Statistical significance was determined
Figure 4 Effect of aqueous extract of Agrimonia pilosa Ledeb. on E2-induced proliferation of MCF-7 cells. Figures were selected as
representative data from three independent experiments. Results are expressed as mean ± SD values. Statistical significance was determined using
the Student’s t-test (*** p < 0.001).
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cell lines, such as MCF-7 [29-31]. The E-Screen assay is
one of the most common reliable and valid tests for the
physiologic action of estrogen. Finally, the expression of
estrogen-related genes may indicate the presence of a
functional estrogen signaling pathway [23,27]. This assay
considers all steps of the ER-signaling pathway, includ-
ing ER-ligand binding, ER expression, ER dimerization,
and available co-activators. Due to the tissue specificity
of endogenous ER-regulated gene (or protein) expres-
sion, the correct marker should be measured in used cell
lines or tissue. In this study, 3 estrogen-dependent
genes, pS2, PR, and cathepsin D, were selected to inves-
tigate the A. pilosa-induced transcriptional responseFigure 5 Effect of ICI 182,780 on Agrimonia pilosa Ledeb.-
induced proliferation in MCF-7 cells. Figures were selected as
representative data from three independent experiments. Results are
expressed as mean ± SD values. Statistical significance was
determined using the Student’s t-test. *** p < 0.001 (vs. without ICI
182,780), ††† p < 0.001, †† p < 0.01 (vs. control).through ER binding. These genes are expressed in MCF-
7 breast cancer cells used in the present study and are
regulated by estrogen, indicating the estrogenic activity
of A. pilosa.
Few previous reports have investigated the chemical
components of A. pilosa. Chemical studies on A. pilosa
have shown the presence of polyphenols such as flavo-
noids [16,32]. Flavonoids and phenolic compounds are
known to possess estrogenic activity [33,34]. Therefore,
many studies on the estrogenic activity of natural plants
attributed their estrogenicity to the presence of flavo-
noids and phenolic compounds [35,36]. Of the known
compounds, the examples of flavonoid phytoestrogens
include quercetin, apigenin, and luteolin. In the current
study, the flavonoids present in the A. pilosa extract
included apigenin-glucuronide (21.81%), apigenin-hexose
(19.46%), and luteolin-glucuronide (13.03%). FurtherFigure 6 Effect of E2 (1 nM) and Agrimonia pilosa Ledeb. (10
μg/mL) on the mRNA levels of estrogen-dependent genes.
Figures were selected as representative data from three
independent experiments. Results are expressed as mean ± SD
values. Statistical significance was determined using ANOVA
followed by a Duncan’s multiple range test (p < 0.05).
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constituents of A. pilosa are underway.
Phytoestrogen was found to show biphasic modula-
tion with regard to MCF-7 cell proliferation. While
genistein stimulates cell proliferation and induces the
estrogen-regulated end product pS2 at low concentra-
tions (1 pM/nM), inhibition of cell growth by ER-
independent cellular mechanisms is observed at higher
concentrations (>10 nM) [37]. Similarly, an abundant
steroidal saponin in ginseng, ginsenoside Rg1, stimulates
ER-dependent human breast cancer cell growth at low,
but not high, concentrations [12]. The ethanol extract of
Ganoderma lucidum has been reported to show both
stimulation (0.1–10 μg/mL) and inhibition (>10 μg/mL)
of MCF-7 cell proliferation [38]. In our study, A. pilosa
aqueous extract also stimulated MCF-7 cell prolifera-
tion at low concentrations (1–10 μg/mL) but not at high
concentrations (100 μg/mL) similar to that of other
known phytoestrogens.
Conclusions
In conclusion, to our knowledge, this study is the first to
investigate the estrogenic activity of A. pilosa aqueous
extract by using several in vitro assays in MCF-7 cells. A.
pilosa aqueous extract bound to ERα and ERβ. In an
MCF-7 cell proliferation assay, A. pilosa stimulated the
proliferation of estrogen receptor-positive MCF-7 cells
in a dose-dependent manner. Proliferation induced by
E2 (1 nM) did not decrease after addition of A. pilosa
aqueous extract. The proliferation induced by A. pilosa
was blocked by addition of the estrogen antagonist, ICI
182,780. Furthermore, A. pilosa treatment increased the
mRNA expression of estrogen-responsive genes (pS2
and PR). It was therefore concluded that the agonist
effects of A. pilosa were primarily mediated through ER.
These in vitro results demonstrate for the first time that
A. pilosa has potent estrogenic activity and may have bene-
ficial effects for postmenopausal women requiring ERT.
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